AKAN
Price
$9.94
Change
-$0.11 (-1.09%)
Updated
Jul 10 closing price
Capitalization
5.38M
Intraday BUY SELL Signals
CABR
Price
$1.34
Change
+$0.01 (+0.75%)
Updated
Jul 10 closing price
Capitalization
12.18M
Intraday BUY SELL Signals
Interact to see
Advertisement

AKAN vs CABR

AKAN vs CABR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
AKAN vs. CABR commentary
Jul 13, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKAN is a Hold and CABR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 13, 2026
Stock price -- (AKAN: $9.94 vs. CABR: $1.34)
Brand notoriety: AKAN and CABR are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AKAN: 1% vs. CABR: 35%
Market capitalization -- AKAN: $5.38M vs. CABR: $12.18M
AKAN [@Pharmaceuticals: Generic] is valued at $5.38M. CABR’s [@Pharmaceuticals: Generic] market capitalization is $12.18M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.01B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKAN’s FA Score shows that 1 FA rating(s) are green whileCABR’s FA Score has 0 green FA rating(s).

  • AKAN’s FA Score: 1 green, 4 red.
  • CABR’s FA Score: 0 green, 5 red.
According to our system of comparison, AKAN is a better buy in the long-term than CABR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKAN’s TA Score shows that 2 TA indicator(s) are bullish while CABR’s TA Score has 6 bullish TA indicator(s).

  • AKAN’s TA Score: 2 bullish, 6 bearish.
  • CABR’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, CABR is a better buy in the short-term than AKAN.

Price Growth

AKAN (@Pharmaceuticals: Generic) experienced а -19.38% price change this week, while CABR (@Pharmaceuticals: Generic) price change was -0.74% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.79%. For the same industry, the average monthly price growth was +3.52%, and the average quarterly price growth was +16.54%.

Industries' Descriptions

@Pharmaceuticals: Generic (-2.79% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CABR($12.2M) has a higher market cap than AKAN($5.38M). CABR YTD gains are higher at: 56.214 vs. AKAN (-3.394). AKAN has higher annual earnings (EBITDA): -2.22M vs. CABR (-4.34M). AKAN has more cash in the bank: 2.52M vs. CABR (2.03M). AKAN has higher revenues than CABR: AKAN (837K) vs CABR (2.75K).
AKANCABRAKAN / CABR
Capitalization5.38M12.2M44%
EBITDA-2.22M-4.34M51%
Gain YTD-3.39456.214-6%
P/E Ratio0.02N/A-
Revenue837K2.75K30,481%
Total Cash2.52M2.03M124%
Total Debt391KN/A-
TECHNICAL ANALYSIS
Technical Analysis
AKANCABR
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
80%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
86%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
Advances
ODDS (%)
N/A
Bullish Trend 27 days ago
90%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 21 days ago
87%
BollingerBands
ODDS (%)
N/A
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
AKAN
Daily Signal:
Gain/Loss:
CABR
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FBRX43.927.22
+19.67%
Forte Biosciences Inc
NAMI3.730.13
+3.76%
Jinxin Technology Holding Company
VNT29.420.50
+1.73%
Vontier Corp
DHX4.010.05
+1.26%
DHI Group
ON95.96-1.91
-1.95%
ON Semiconductor Corp

AKAN and

Correlation & Price change

A.I.dvisor tells us that AKAN and TRLV have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AKAN and TRLV's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKAN
1D Price
Change %
AKAN100%
-1.09%
TRLV - AKAN
27%
Poorly correlated
-2.49%
SNOA - AKAN
25%
Poorly correlated
N/A
TLRY - AKAN
25%
Poorly correlated
+0.68%
OGI - AKAN
25%
Poorly correlated
-1.47%
CRON - AKAN
25%
Poorly correlated
-1.08%
More

CABR and

Correlation & Price change

A.I.dvisor tells us that CABR and GLAS have been poorly correlated (+8% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CABR and GLAS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CABR
1D Price
Change %
CABR100%
+0.75%
GLAS - CABR
8%
Poorly correlated
+1.72%
AKAN - CABR
7%
Poorly correlated
-1.09%
IXHL - CABR
7%
Poorly correlated
+0.59%
SHPH - CABR
6%
Poorly correlated
-10.98%
TEVA - CABR
6%
Poorly correlated
-0.45%
More